Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Notes Payables (2023 - 2025)

Historic Notes Payables for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $11.2 million.

  • Zhengye Biotechnology Holding's Notes Payables changed N/A to $11.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.2 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2024, which is 831.93% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Notes Payables stood at $11.2 million for Q2 2025.
  • Zhengye Biotechnology Holding's Notes Payables' 5-year high stood at $11.2 million during Q2 2025, with a 5-year trough of $10.4 million in Q4 2024.
  • Over the past 3 years, Zhengye Biotechnology Holding's median Notes Payables value was $11.1 million (recorded in 2023), while the average stood at $10.9 million.
  • Data for Zhengye Biotechnology Holding's Notes Payables shows a peak YoY increase of 656.28% (in 2024) and a maximum YoY decrease of 656.28% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Notes Payables stood at $11.1 million in 2023, then fell by 6.56% to $10.4 million in 2024, then grew by 7.87% to $11.2 million in 2025.
  • Its Notes Payables was $11.2 million in Q2 2025, compared to $10.4 million in Q4 2024 and $11.1 million in Q4 2023.